Amicus Therapeutics (FOLD) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Amicus Therapeutics Announces Second Quarter 2022 Financial Results
August 4, 2022 7:00 AM EDT1H22 Galafold® Revenue of $159.4M, reflecting 11% Sales Growth with Operational Growth of 18%, Partly Offset by Currency Headwinds of 7%
On-Track to Deliver Full-Year Double-Digit Revenue Growth of 15-20%Â at Constant Exchange Rates
Advancing U.S. and EU Regulatory Reviews and Launch Preparations for AT-GAA in Pompe Disease
3 Newly Issued U.S. Composition of Matter Patents for... More



